Zerbor/iStock via Getty Images
Exact Sciences (NASDAQ:EXAS) shares rose in the post market hours as the company raised its full-year revenue guidance range, despite an earnings miss, banking on strong demand for its diagnostic tests.
The company raised its full-year revenue guidance range to